You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Pagnon de la Vega M, Syvänen S, Giedraitis V, et al. (2024) Altered amyloid-β structure markedly reduces gliosis in the brain of mice harboring the Uppsala APP deletion. Acta Neuropathologica Communications. 12: 22
Lannfelt L. (2023) A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease. Upsala Journal of Medical Sciences. 128
Hampel H, Hu Y, Hardy J, et al. (2023) The amyloid-β pathway in Alzheimer's disease: a plain language summary. Neurodegenerative Disease Management
Condello C, Maxwell AM, Castillo E, et al. (2022) Aβ and tau prions feature in the neuropathogenesis of Down syndrome. Proceedings of the National Academy of Sciences of the United States of America. 119: e2212954119
Söderberg L, Johannesson M, Nygren P, et al. (2022) Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics
Pagnon de la Vega M, Näslund C, Brundin R, et al. (2022) Mutation analysis of disease causing genes in patients with early onset or familial forms of Alzheimer's disease and frontotemporal dementia. Bmc Genomics. 23: 99
Rofo F, Buijs J, Falk R, et al. (2021) Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta. Translational Neurodegeneration. 10: 38
Hampel H, Hardy J, Blennow K, et al. (2021) The Amyloid-β Pathway in Alzheimer's Disease. Molecular Psychiatry
Pagnon de la Vega M, Giedraitis V, Michno W, et al. (2021) The deletion causes early onset autosomal dominant Alzheimer's disease by altering APP processing and increasing amyloid β fibril formation. Science Translational Medicine. 13
Johannesson M, Sahlin C, Söderberg L, et al. (2021) Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease. Molecular and Cellular Neurosciences. 114: 103641